^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    OncoSELECT

    Company:
    OncoDNA
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    9ms
    Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial (ESMO 2023)
    Table: 2237P Conclusions Independently of RAS mutation, existing adaptive immune response within metastases is associated with treatment benefit. ctDNA decrease is associated with tumor response.
    P2 data • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • RAS (Rat Sarcoma Virus)
    |
    RAS mutation • RAS wild-type
    |
    OncoSELECT
    |
    Erbitux (cetuximab) • Bavencio (avelumab) • irinotecan • Avetux (rituximab biosimilar)
    3years
    Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions. (PubMed, Cancers (Basel))
    "Several alternative approaches have been shown to break the resistance of PDACs to VSV without compromising VSV oncoselectivity, including (i) combinations of VSV with JAK1/2 inhibitors (such as ruxolitinib); (ii) triple combinations of VSV with ruxolitinib and polycations improving both VSV replication and attachment; (iii) combinations of VSV with chemotherapeutic drugs (such as paclitaxel) arresting cells in the G2/M phase; (iv) arming VSV with p53 transgenes; (v) directed evolution approach producing more effective OVs. The latter study demonstrated impressive long-term genomic stability of complex VSV recombinants encoding large transgenes, supporting further clinical development of VSV as safe therapeutics for PDAC."
    Oncolytic virus • Journal • Review
    |
    OncoSELECT
    |
    paclitaxel • Jakafi (ruxolitinib)